ADAMTS13 and thrombotic thrombocytopenic purpura: Novel TTP treatments (caplacizumab) can improve TTP outcomes, but more effective use of existing treatments (TPE, immune suppression) and care coordination (TMA Team, ADAMTS13 surveillance) can also be beneficial [2,3,7,25,38,39].